Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, reported a net loss of $24.48 million for the year ended December 31, 2025, compared to a net loss of $1.31 million for the previous year. The company's revenue for 2025 was $6,202, derived from the sale of nutraceutical products, while there was no revenue in 2024. Cost of revenue was $6,318 for 2025. The company's operating expenses increased significantly, with general and administrative expenses rising to $17.64 million in 2025 from $940,421 in 2024, research and development expenses increasing to $923,914 in 2025 from $144,356 in 2024, and sales and marketing expenses increasing to $789,829 in 2025 from $126,094 in 2024.
The increased net loss was primarily attributed to a rise in operating expenses and interest expenses. Interest expense for 2025 was $8.53 million, compared to $97,988 in 2024, due to the accrual of interest on convertible notes and the amortization of debt discounts. The company also reported a change in the fair value of liabilities of $3.86 million and a loss on extinguishment of debt of $364,109. As of December 31, 2025, Aspire had a working capital deficit of $6.28 million and cash of $1.00 million.
Strategic developments during 2025 included the completion of a reverse recapitalization with PowerUp Acquisition Corp., which resulted in Aspire Biopharma, Inc. becoming a wholly-owned subsidiary of Aspire Biopharma Holdings, Inc. The company also entered into a Securities Purchase Agreement, issuing convertible debentures for $3.75 million, and a new Purchase Agreement for an equity line of credit of up to $100 million. Aspire is focusing on developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company is also pursuing licensing and collaboration agreements.
Key operational developments included the manufacturing of a cGMP batch of high-dose aspirin and the completion of clinical trials in Florida. The company submitted a pre-IND written request to the FDA in October 2025 and received a positive response in November 2025. Aspire plans to conduct additional clinical trials and submit a section 505(b)(2) NDA for its aspirin product to the FDA. The company is also developing formulations for other products, including melatonin, vitamins, ED medication, and caffeine products. As of March 27, 2026, there were 5,024,124 shares of Common Stock issued and outstanding.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma is an early-stage biopharmaceutical company developing innovative sublingual drug delivery technologies. Its focus includes creating fast-acting formulations for known drugs like aspirin, with potential applications in pain management, stroke, and heart attack prevention. The company aims to commercialize products through licensing, collaborations, and direct sales, leveraging proprietary formulations, patents, and strategic partnerships in the pharmaceutical and nutraceutical markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.